KAI Pharmaceuticals Announces Phase 1 Results Of KAI-4169 For The Treatment Of Secondary Hyperparathyroidism (SHPT)
Links shared publicly online about this topic.
- 1,004total visits
KAI Pharmaceuticals Announces Phase 1 Results Of KAI-4169 For The Treatment Of Secondary Hyperparathyroidism (SHPT)
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agen
View full resource at medicalnewstoday.com
Tags: Parathyroid Disorder, Drug, Pharma, Phase 1 Clinical Trial
Most Recently Shared on July 22, 2010 at 2:06 pm By:
KAI Pharmaceuticals Announces Phase 1 Results Of KAI-4169 For The Treatment Of Secondary Hyperparathyroidism (SHPT) http://mnt.to/3Grr
Also Shared By:
KAI Pharmaceuticals Announces Initiation Of Phase 1b Study Of KAI-4169 For The Treatment Of Secondary Hyperparathyroidism (SHPT)
medicalnewstoday.com — “KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 1b study of KAI-4169, a novel pharmaceutical agent b” View full resource at medicalnewstoday.com
Most Recently Shared on September 29, 2010 at 2:05 pm By:
KAI Pharmaceuticals Announces Initiation Of Phase 1b Study Of KAI-4169 For The Treatment Of Secondary Hyperparathyroid... http://mnt.to/3Kth
Advertisement
Endocrinology Wisdom
@EndocrinologyOW
KAI Pharmaceuticals Announces Phase 1 Results Of KAI-4169 For The Treatment Of Secondary Hyperparathyroidism (SHPT... http://mnt.to/f/3Grr
1 year ago...